Rofecoxib decreases renal injury in obese Zucker rats - PubMed (original) (raw)
. 2004 Dec;107(6):561-70.
doi: 10.1042/CS20040125.
Affiliations
- PMID: 15307815
- DOI: 10.1042/CS20040125
Rofecoxib decreases renal injury in obese Zucker rats
Aparajita Dey et al. Clin Sci (Lond). 2004 Dec.
Abstract
The present study tested the hypothesis that altered vascular regulation of arachidonic acid enzymes in obese Zucker rats contributes to renal damage. Protein expression of CYP450 (cytochrome P450) and COX (cyclo-oxygenase) enzymes in renal microvessels was studied in obese and lean Zucker rats at 20-21 weeks of age. Body weight and blood glucose averaged 649+/-13 g and 142+/-10 mg/dl in obese Zucker rats compared with 437+/-10 g and 111+/-5 mg/dl in age-matched lean Zucker rats. Renal microvascular CYP4A and COX-2 protein levels were increased and CYP2C protein levels decreased in obese Zucker rats. TX (thromboxane) B2 excretion was 2-fold higher and PG (prostaglandin) E2 excretion significantly lower in obese Zucker rats. Additional studies investigated the ability of the COX-2 inhibitor, rofecoxib, to slow the progression of renal injury in obese Zucker rats. Rofecoxib treatment decreased urinary PGF2alpha and 8-isoprostane levels in obese Zucker rats. Renal microvessel mRNA expression of pro-inflammatory chemokines was decreased in COX-2-inhibitor-treated obese Zucker rats. Urinary albumin excretion, an index of kidney damage, averaged 95+/-11 mg/day in vehicle-treated and 9+/-1 mg/day in rofecoxib-treated obese Zucker rats. Glomerulosclerosis, characterized by mesangial expansion, tubulo-interstitial fibrosis and extracellular matrix accumulation, was prominent in obese Zucker rats compared with a lack of damage in age-matched lean Zucker rats and rofecoxib-treated obese Zucker rats. These results suggest that altered vascular arachidonic acid enzymes contribute to the renal damage, and that COX-2 inhibition decreases glomerular injury in obese Zucker rats.
Similar articles
- Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria.
Dey A, Williams RS, Pollock DM, Stepp DW, Newman JW, Hammock BD, Imig JD. Dey A, et al. Obes Res. 2004 Aug;12(8):1278-89. doi: 10.1038/oby.2004.162. Obes Res. 2004. PMID: 15340111 - Cyclooxygenase 1 and/or 2 blockade ameliorates the renal tissue damage triggered by ischemia and reperfusion injury.
Feitoza CQ, Câmara NO, Pinheiro HS, Gonçalves GM, Cenedeze MA, Pacheco-Silva A, Santos OF. Feitoza CQ, et al. Int Immunopharmacol. 2005 Jan;5(1):79-84. doi: 10.1016/j.intimp.2004.09.024. Int Immunopharmacol. 2005. PMID: 15589463 - Cyclooxygenase-2 and the kidney: functional and pathophysiological implications.
Harris RC. Harris RC. J Hypertens Suppl. 2002 Sep;20(6):S3-9. J Hypertens Suppl. 2002. PMID: 12683421 Review. - Roles of lipid mediators in kidney injury.
Hao CM, Breyer MD. Hao CM, et al. Semin Nephrol. 2007 May;27(3):338-51. doi: 10.1016/j.semnephrol.2007.02.008. Semin Nephrol. 2007. PMID: 17533010 Review.
Cited by
- Flavocoxid attenuates gentamicin-induced nephrotoxicity in rats.
El-Kashef DH, El-Kenawi AE, Suddek GM, Salem HA. El-Kashef DH, et al. Naunyn Schmiedebergs Arch Pharmacol. 2015 Dec;388(12):1305-15. doi: 10.1007/s00210-015-1164-8. Epub 2015 Aug 15. Naunyn Schmiedebergs Arch Pharmacol. 2015. PMID: 26272642 - Role of COX-2/mPGES-1/prostaglandin E2 cascade in kidney injury.
Jia Z, Zhang Y, Ding G, Heiney KM, Huang S, Zhang A. Jia Z, et al. Mediators Inflamm. 2015;2015:147894. doi: 10.1155/2015/147894. Epub 2015 Feb 1. Mediators Inflamm. 2015. PMID: 25729216 Free PMC article. Review. - AMP-activated protein kinase activation ameliorates eicosanoid dysregulation in high-fat-induced kidney disease in mice.
Declèves AE, Mathew AV, Armando AM, Han X, Dennis EA, Quehenberger O, Sharma K. Declèves AE, et al. J Lipid Res. 2019 May;60(5):937-952. doi: 10.1194/jlr.M088690. Epub 2019 Mar 12. J Lipid Res. 2019. PMID: 30862696 Free PMC article. - Arachidonic acid metabolism as a therapeutic target in AKI-to-CKD transition.
Li XJ, Suo P, Wang YN, Zou L, Nie XL, Zhao YY, Miao H. Li XJ, et al. Front Pharmacol. 2024 Mar 8;15:1365802. doi: 10.3389/fphar.2024.1365802. eCollection 2024. Front Pharmacol. 2024. PMID: 38523633 Free PMC article. Review. - Prostaglandins in the pathogenesis of kidney diseases.
Li Y, Xia W, Zhao F, Wen Z, Zhang A, Huang S, Jia Z, Zhang Y. Li Y, et al. Oncotarget. 2018 May 29;9(41):26586-26602. doi: 10.18632/oncotarget.25005. eCollection 2018 May 29. Oncotarget. 2018. PMID: 29899878 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials